Figures & data
Table I. Patient characteristics at diagnosis.
Table II. Treatment prior to radiation. Median represents median number of treatments per patient.
Table III. Patent characteristics at radiation.
Table IV. Radiation treatment.
Figure 1. Tumor response to radiotherapy. Percent change in tumor size at time of maximal response to radiotherapy for all evaluable patients (n=24). RECIST category response to radiotherapy is also shown. PD – progressive disease, SD – stable disease, PR – partial response.
Figure 2. Outcomes for the study population. A. Overall survival after XRT (OS). B. In field progression free survival after XRT (PFS). C. Biochemical failure free survival after XRT (Biochemical PFS). D. Distant metastasis free survival after XRT (DMFS). E. Median and one year outcomes. NR – Not reached.
Figure 3. The effect of BED on outcomes in unresectable HCC. A. Overall survival after XRT (OS) stratified by BED <75 vs. BED ≥75. B. In field progression free survival after XRT (PFS) stratified by BED <75 vs. BED >75. C. Biochemical recurrence free survival after XRT (Biochemical PFS) stratified by BED <75 vs. BED >75. D. Distant metastasis free survival after XRT (DMFS) stratified by BED <75 vs. BED ≥75. NR – Not reached.
Table 5. Complications and toxicity due to radiation.